PapersFlow Research Brief
Estrogen and related hormone effects
Research Guide
What is Estrogen and related hormone effects?
Estrogen and related hormone effects are the physiological and pathological outcomes produced when estrogenic hormones act through estrogen receptors and interconnected endocrine signaling pathways to regulate gene expression and tissue function across the lifespan.
The research literature on estrogen and related hormone effects includes 122,764 works, spanning molecular receptor biology, clinical hormone therapy, and estrogen-targeted cancer prevention and treatment.
Research Sub-Topics
Estrogen Receptor Alpha Signaling
This sub-topic elucidates ERα genomic and non-genomic actions, co-regulator recruitment, and ligand-selective conformations. Researchers study selective estrogen receptor modulators (SERMs) mechanisms.
Estrogen Effects on Cardiovascular System
This sub-topic investigates estrogen modulation of endothelial function, lipid profiles, and vascular inflammation. Researchers analyze HRT impacts on atherosclerosis and thrombosis risks.
Selective Estrogen Receptor Modulators
This sub-topic profiles SERM tissue-specific agonist/antagonist activities including raloxifene and bazedoxifene. Researchers develop next-generation SERMs for osteoporosis and breast cancer prevention.
Estrogen Neuroprotection and Brain Function
This sub-topic explores estrogen's roles in synaptic plasticity, amyloid-beta clearance, and neuroinflammation. Researchers investigate timing hypothesis for menopause-related cognitive decline.
Aromatase Inhibitors in Breast Cancer
This sub-topic evaluates third-generation AIs like anastrozole for adjuvant therapy in postmenopausal ER+ breast cancer. Researchers compare AI efficacy and bone health impacts versus tamoxifen.
Why It Matters
Estrogen and related hormone effects matter because they directly inform high-stakes clinical decisions in menopause management, cardiovascular risk, and breast cancer prevention and prognosis. In postmenopausal hormone therapy, Rossouw (2002) reported in "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial" that, over an average 5.2-year follow-up, overall health risks exceeded benefits for combined estrogen plus progestin in healthy postmenopausal US women, while all-cause mortality was not affected during the trial. In secondary prevention cardiology, Hulley (1998) showed in "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" that, during an average follow-up of 4.1 years, oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease events, and increased thromboembolic events and gallbladder disease. In women with hysterectomy, Anderson et al. (2004) found in "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" that conjugated equine estrogen increased stroke risk, decreased hip fracture risk, and did not affect coronary heart disease incidence over an average of 6.8 years, with a possible reduction in breast cancer risk requiring further investigation. In breast oncology, Fisher et al. (1998) concluded in "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" that tamoxifen decreases the incidence of invasive and noninvasive breast cancer and can be appropriate for prevention in many women at increased risk despite side effects, and Paik et al. (2004) reported in "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" that a recurrence score was validated to quantify the likelihood of distant recurrence in tamoxifen-treated, node-negative, estrogen-receptor-positive breast cancer.
Reading Guide
Where to Start
Start with Evans (1988) "The Steroid and Thyroid Hormone Receptor Superfamily" because it provides a compact conceptual basis for how steroid receptors control transcription, which is necessary to interpret downstream clinical and translational findings about estrogenic effects.
Key Papers Explained
A useful through-line begins with receptor theory and classification: Evans (1988) "The Steroid and Thyroid Hormone Receptor Superfamily" and Mangelsdorf et al. (1995) "The nuclear receptor superfamily: The second decade" establish estrogen receptors as transcription-regulating nuclear receptors within a broader superfamily. Kuiper et al. (1996) "Cloning of a novel receptor expressed in rat prostate and ovary." extends the receptor concept by identifying a novel receptor expressed in multiple tissues, motivating the expectation of tissue-specific estrogen effects. The clinical consequence of these mechanisms is then tested at scale in Hulley (1998) "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" and Rossouw (2002) "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial," which document lack of coronary benefit and an overall risk profile exceeding benefit for combined therapy under the reported follow-up periods. Anderson et al. (2004) "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" contrasts estrogen-only outcomes (stroke, hip fracture, coronary endpoints) and frames regimen- and population-dependent effects. In breast cancer, Fisher et al. (1998) "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" demonstrates prevention utility, while Paik et al. (2004) "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" adds prognostic stratification within estrogen-receptor-positive disease treated with tamoxifen.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
An advanced reading path is to synthesize regimen-specific outcome patterns across the large randomized trials: compare combined estrogen-plus-progestin findings in "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" (1998) and "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial" (2002) with estrogen-only findings in "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" (2004), then connect these results to estrogen-receptor-positive breast cancer risk modification and stratified prognosis in "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" (1998) and "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" (2004).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Risks and Benefits of Estrogen Plus Progestin in Healthy Postm... | 2002 | JAMA | 15.6K | ✓ |
| 2 | Effects of chemotherapy and hormonal therapy for early breast ... | 2005 | The Lancet | 7.6K | ✕ |
| 3 | The Steroid and Thyroid Hormone Receptor Superfamily | 1988 | Science | 7.6K | ✓ |
| 4 | The nuclear receptor superfamily: The second decade | 1995 | Cell | 6.9K | ✓ |
| 5 | A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, ... | 2004 | New England Journal of... | 6.2K | ✓ |
| 6 | Randomized Trial of Estrogen Plus Progestin for Secondary Prev... | 1998 | JAMA | 6.2K | ✕ |
| 7 | Tamoxifen for Prevention of Breast Cancer: Report of the Natio... | 1998 | JNCI Journal of the Na... | 5.5K | ✓ |
| 8 | Cloning of a novel receptor expressed in rat prostate and ovary. | 1996 | Proceedings of the Nat... | 4.8K | ✓ |
| 9 | The Effect of Vitamin E and Beta Carotene on the Incidence of ... | 1994 | New England Journal of... | 4.7K | ✓ |
| 10 | Effects of Conjugated Equine Estrogen in Postmenopausal Women ... | 2004 | JAMA | 4.4K | ✓ |
In the News
Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model
# Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model Merchenthaler, Istvan Jozsef Prokai, Laszlo Puche, Adam C.
FDA approves Veozah (Fezolinetant) for menopausal symptoms
the quality of life for many women during menopause[ 1 ]. The recent development of neurokinin-3 receptor (NK3R) antagonists represents a novel therapeutic approach. On 12 May 2023, the National In...
New menopause drug without hormones approved by FDA ...
has historically been limited.
Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management
fezolinetant, a neurokinin-3 receptor (NK3R) antagonist approved by the FDA in 2023, which targets hypothalamic KNDy neurons to reduce VMS frequency by over 50% without hormonal effects ( 15 ). Eme...
Natural strategies to optimize estrogen levels in aging women: mini review
### 6.5 Resveratrol: breakthrough in bone health
Code & Tools
## eapath: Computational Models for Estrogen and Androgen Receptor Activity ### Installation eapath contains both data and code to calculate estr...
## About Repository of codes and data for Estrogen Receptor Alpha QSAR modeling ### Resources Readme ### Uh oh! There was an error while loading....
menstrualcycleR is a package for preparing longitudinal menstrual cycle data for continuous data analysis. ### License GPL-3.0 license
| ## Repository files navigation # tcpl: The ToxCast Data Analysis Pipeline Supporting Accessible Bioactivity Data for Toxicology
**Overview:** This package has been developed specifically for wildlife endocrinologist. The package contains data analysis tools that facilitate a...
Recent Preprints
The Role of Estrogen Receptors in Menopausal Mental Health ...
## 3\. Estrogen and Menopausal Mental Health
Study Sheds New Light on How Hormones Influence ...
A new study by a team of scientists focusing on the female hormone estrogen further illuminates the nature of these processes. In a series of experiments with laboratory rats, it finds that the neu...
Emotional and cognitive effects of menopause ...
mental health.
Estrogen modulates reward prediction errors and reinforcement learning
Estrogenic hormones, including 17β-estradiol, rhythmically fluctuate over the reproductive cycle in mammalian females and act on estrogen receptors, which can regulate protein expression via transc...
Estrogen dominance drives distinct patterns of brain plasticity
Gonadal hormones shape brain structure across the lifespan. Using dense sampling in two female participants with typical cycles, one with endometriosis, and one using oral contraceptives, we show t...
Latest Developments
Recent research highlights significant developments in estrogen and hormone effects, including a study from January 2026 suggesting that sex hormones like estradiol may play an important role in long-term heart health, especially for men with type 2 diabetes (Johns Hopkins Medicine, news.vt.edu). Additionally, advances in female physiology research are informing broader health insights, as discussed by Holly Ingraham in January 2026 (Virginia Tech News). Furthermore, a notable update from the FDA in November 2025 removed the black box warning from low-dose vaginal estrogen products, reflecting evolving regulatory perspectives (Conrad Pearson, FDA.gov).
Sources
Frequently Asked Questions
What are estrogen and related hormone effects?
Estrogen and related hormone effects are the biological outcomes of estrogenic hormones acting through estrogen receptors and related endocrine pathways to alter transcriptional programs and tissue physiology. The mechanistic basis for hormone-driven transcriptional regulation is framed by receptor superfamily concepts described in Evans (1988) "The Steroid and Thyroid Hormone Receptor Superfamily" and Mangelsdorf et al. (1995) "The nuclear receptor superfamily: The second decade".
How do estrogen receptors fit into the broader nuclear receptor system?
Evans (1988) stated in "The Steroid and Thyroid Hormone Receptor Superfamily" that analyses of steroid receptors are important for understanding molecular details of transcriptional control and how transacting factors contribute to cell identity and function. Mangelsdorf et al. (1995) in "The nuclear receptor superfamily: The second decade" positioned nuclear receptors as a superfamily framework that includes steroid hormone receptors such as estrogen receptors.
Which major clinical trials most directly shaped evidence on postmenopausal estrogen therapy risks and benefits?
Rossouw (2002) in "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial" reported that overall health risks exceeded benefits for combined estrogen plus progestin over an average 5.2-year follow-up, with all-cause mortality not affected during the trial. Anderson et al. (2004) in "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" reported increased stroke risk, decreased hip fracture risk, and no effect on coronary heart disease incidence over an average 6.8 years.
Why did estrogen plus progestin not reduce coronary heart disease events in secondary prevention studies?
Hulley (1998) reported in "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" that, over an average follow-up of 4.1 years, conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease events. The same trial reported increased thromboembolic events and gallbladder disease, indicating clinically relevant harms alongside the lack of coronary benefit in that population.
How is tamoxifen used to modify estrogen-related breast cancer risk and outcomes?
Fisher et al. (1998) reported in "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study" that tamoxifen decreases the incidence of invasive and noninvasive breast cancer and can be appropriate for prevention in many women at increased risk despite side effects. Paik et al. (2004) reported in "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" that a recurrence score was validated to quantify the likelihood of distant recurrence in tamoxifen-treated, node-negative, estrogen-receptor-positive breast cancer.
Which discoveries expanded the concept of estrogen receptor diversity?
Kuiper et al. (1996) reported in "Cloning of a novel receptor expressed in rat prostate and ovary." the cloning of a novel member of the nuclear receptor superfamily expressed in rat prostate and ovary. The paper described a cDNA encoding a 485–amino acid protein with a calculated molecular weight of 54.2 kDa, supporting the idea that estrogen signaling can involve more than a single receptor entity.
Open Research Questions
- ? How can nuclear-receptor transcriptional control principles summarized in "The Steroid and Thyroid Hormone Receptor Superfamily" (1988) be operationalized to predict tissue-specific benefits versus harms observed in "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial" (2002)?
- ? Which mechanistic differences between combined estrogen-plus-progestin regimens and estrogen-only regimens best explain the divergent clinical outcome profiles reported in "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" (1998) versus "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" (2004)?
- ? How should recurrence-risk tools such as the recurrence score in "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" (2004) be integrated with trial-level evidence on hormonal therapy benefits summarized in "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials" (2005)?
- ? What is the functional significance in humans of receptor diversity implied by "Cloning of a novel receptor expressed in rat prostate and ovary." (1996) for predicting estrogenic effects across non-reproductive tissues?
- ? Which outcome domains (e.g., thromboembolic events, stroke, fracture) should be prioritized in future risk–benefit models, given the specific harms and non-benefits reported in "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women" (1998) and "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy" (2004)?
Recent Trends
The provided dataset indicates a very large published literature (122,764 works) on estrogen and related hormone effects, but it does not provide a 5-year growth rate.
Within the most-cited clinical evidence base listed here, large randomized trials in postmenopausal women report regimen- and population-dependent tradeoffs over multi-year follow-up periods: Rossouw reported an overall risk profile exceeding benefit over 5.2 years for combined estrogen plus progestin in healthy postmenopausal women, Hulley (1998) reported no reduction in coronary heart disease events over 4.1 years with combined therapy in women with established coronary disease alongside increased thromboembolic events and gallbladder disease, and Anderson et al. (2004) reported increased stroke risk and decreased hip fracture risk over 6.8 years with conjugated equine estrogen in women with hysterectomy.
2002In parallel, highly cited breast cancer studies emphasize estrogen-pathway targeting and stratification: Fisher et al. reported reduced incidence of invasive and noninvasive breast cancer with tamoxifen prevention, and Paik et al. (2004) reported validation of a recurrence score for distant recurrence risk in tamoxifen-treated, node-negative, estrogen-receptor-positive breast cancer.
1998Research Estrogen and related hormone effects with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Estrogen and related hormone effects with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.